iFabrick (IFA) Investor presentation summary

Business overview and platform

• Operates a capital-light, clinically validated textile technology platform with proprietary chemistry IP and global distribution.

• Generates revenue through three streams: textile technologies, finished products, and solution bras & accessories.

• Proprietary chemistries like PROTX2Ⓡ and ecoPEL™ are licensed to global brands, driving growth in healthcare, performance, and consumer textiles.

• Asset-light model with manufacturing in nine countries and a focus on integrating into existing global supply chains.

• Coconut Grove Intimates provides a profitable, cash-generative foundation supporting growth initiatives.

Technology and product ecosystem

• 18 proprietary, patented or patent-pending textile technologies address antimicrobial, antiviral, moisture, water repellency, cooling, UV, and wellness needs.

• PROTX2Ⓡ is the only antimicrobial textile validated by a peer-reviewed clinical trial, offering medical-grade protection and durability.

• Finished products span scrubs, activewear, underwear, swimwear, footwear, bedding, and home textiles.

• Monetizes technology both as a chemical/platform sale and as higher-value finished goods.

Commercial reach and retail execution

• Technologies and products are embedded with major global brands and retailers, including Walmart, Costco, Target, Kohl's, Amazon, and Macy's.

• Retail programs include Walmart U.S. (scrubs, period panties, bras), Costco Canada (swimwear, essentials), and Target/Kohl's (Frontline scrubs, The Natural leakproof underwear).

• Walmart U.S. rollout of scrubs expanded from 350 to 1,400 stores following clinical validation.